Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2016

23.04.2016 | Original Article

YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo

verfasst von: De Cai, Zhiqing Qiu, Weimin Yao, Yuyu Liu, Haixiang Huang, Sihai Liao, Qun Luo, Liming Xie, Zhixiu Lin

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Microtubules play a central role in various fundamental cell functions and thus become an attractive target for cancer therapy. A novel compound YSL-12 is a combretastatin A-4 (CA-4) analogue with more stability. We investigated its anti-tumor activity and mechanisms in vitro and in vivo for the first time.

Methods

Cytotoxicity was evaluated by MTT method. In vitro microtubule polymerization assay was performed using a fluorescence-based method by multifunction fluorescence microplate reader. Intracellular microtubule network was detected by immunofluorescence method. Cell cycle analysis and apoptosis were measured by flow cytometry. Metabolic stability was recorded by liquid chromatography–ultraviolet detection and liquid chromatography–mass spectrometry. In vivo anti-tumor activity was assessed using HT-29 colon carcinoma xenografts established in BALB/c nude mice.

Results

YSL-12 displayed nanomolar-level cytotoxicity against various human cancer cell lines. A high selectivity toward normal cells and potent activity toward drug-resistant cells were also observed. YSL-12 was identified as tubulin polymerization inhibitor evidenced by effectively inhibits tubulin polymerization and heavily disrupted microtubule networks in living HT-29 cells. YSL-12 displayed potent disruption effect of pre-established tumor vasculature in vitro. In addition, YSL-12 treatment also caused cell cycle arrest in the G2/M phase and induced cell apoptosis in a dose-dependent manner. In vitro metabolic stability study revealed YSL-12 displayed considerable better stability than CA-4 in liver microsomes. In vivo, YSL-12 delayed tumor growth with 69.4 % growth inhibition.

Conclusions

YSL-12 is a promising microtubule inhibitor that has great potential for the treatment of colon carcinoma in vitro and in vivo and worth being a candidate for further development of cancer therapy.
Literatur
1.
Zurück zum Zitat Wade RH (2009) On and around microtubules: an overview. Mol Biotechnol 43(1073–6085):177–191CrossRefPubMed Wade RH (2009) On and around microtubules: an overview. Mol Biotechnol 43(1073–6085):177–191CrossRefPubMed
3.
Zurück zum Zitat Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(1474–175X):253–265CrossRefPubMed Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(1474–175X):253–265CrossRefPubMed
4.
Zurück zum Zitat Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, Hamel E (1988) Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 34(2):200–208PubMed Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, Hamel E (1988) Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 34(2):200–208PubMed
7.
Zurück zum Zitat Pettit GR, Sb Singh, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45(2):209–211CrossRefPubMed Pettit GR, Sb Singh, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45(2):209–211CrossRefPubMed
8.
Zurück zum Zitat Cirla A, Mann J (2003) Combretastatins: from natural products to drug discovery. Nat Prod Rep 20(6):558–564CrossRefPubMed Cirla A, Mann J (2003) Combretastatins: from natural products to drug discovery. Nat Prod Rep 20(6):558–564CrossRefPubMed
9.
Zurück zum Zitat Bedford SBQ, Charmaine P, Rathbone Daniel L, Slack John A, Griffin Roger J, Stevens Malcolm F G (1996) Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4. Bioorg Med Chem Lett 6:157–160. doi:10.1016/0960-894X(95)00580-M CrossRef Bedford SBQ, Charmaine P, Rathbone Daniel L, Slack John A, Griffin Roger J, Stevens Malcolm F G (1996) Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4. Bioorg Med Chem Lett 6:157–160. doi:10.​1016/​0960-894X(95)00580-M CrossRef
11.
Zurück zum Zitat Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Brit J Cancer 71(4):705–711CrossRefPubMedPubMedCentral Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Brit J Cancer 71(4):705–711CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Magalhães HIF, Bezerra DP, Cavalcanti BC, Wilke DV, Rotta R, Lima DP, Beatriz A, Alves APNN, Bitencourt DFS, Figueiredo IST, Alencar NMN, Costa-Lotufo LV, Moraes MO, Pessoa C (2010) In vitro and in vivo antitumor effects of (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone. Cancer Chemother Pharmacol 68(1):45–52. doi:10.1007/s00280-010-1446-2 CrossRefPubMed Magalhães HIF, Bezerra DP, Cavalcanti BC, Wilke DV, Rotta R, Lima DP, Beatriz A, Alves APNN, Bitencourt DFS, Figueiredo IST, Alencar NMN, Costa-Lotufo LV, Moraes MO, Pessoa C (2010) In vitro and in vivo antitumor effects of (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone. Cancer Chemother Pharmacol 68(1):45–52. doi:10.​1007/​s00280-010-1446-2 CrossRefPubMed
13.
Zurück zum Zitat Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51(1):43–52. doi:10.1007/s00280-002-0529-0 CrossRefPubMed Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51(1):43–52. doi:10.​1007/​s00280-002-0529-0 CrossRefPubMed
14.
Zurück zum Zitat Bonne D, Heuséle C, Simon C, Pantaloni D (1985) 4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules. J Biol Chem 260(5):2819–2825PubMed Bonne D, Heuséle C, Simon C, Pantaloni D (1985) 4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules. J Biol Chem 260(5):2819–2825PubMed
15.
Zurück zum Zitat Diaz JF, Andreu JM (1993) Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32(11):2747–2755CrossRefPubMed Diaz JF, Andreu JM (1993) Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32(11):2747–2755CrossRefPubMed
17.
Zurück zum Zitat Chen C-T, Gan Y, Au JLS, Wientjes MG (1998) Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res 58(13):2777–2783PubMed Chen C-T, Gan Y, Au JLS, Wientjes MG (1998) Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res 58(13):2777–2783PubMed
18.
Zurück zum Zitat Ouyang L, Luo Y, Tian M, Zhang SY, Lu R, Wang JH, Kasimu R, Li X (2014) Plant natural products: from traditional compounds to new emerging drugs in cancer therapy. Cell Prolif 47(6):506–515. doi:10.1111/cpr.12143 CrossRefPubMed Ouyang L, Luo Y, Tian M, Zhang SY, Lu R, Wang JH, Kasimu R, Li X (2014) Plant natural products: from traditional compounds to new emerging drugs in cancer therapy. Cell Prolif 47(6):506–515. doi:10.​1111/​cpr.​12143 CrossRefPubMed
19.
Zurück zum Zitat Pettit GR, Rhodes MR, Herald DL, Chaplin DJ, Stratford MR, Hamel E, Pettit RK, Chapuis JC, Oliva D (1998) Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anticancer Drug Des 13(8):981–993PubMed Pettit GR, Rhodes MR, Herald DL, Chaplin DJ, Stratford MR, Hamel E, Pettit RK, Chapuis JC, Oliva D (1998) Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anticancer Drug Des 13(8):981–993PubMed
20.
Zurück zum Zitat Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, Nihei Y, Suga Y, Morinaga Y, Akiyama Y, Tsuji T (1998) Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analogues. Bioorg Med Chem Lett 8(22):3153–3158. doi:10.1016/S0960-894X(98)00579-4 CrossRefPubMed Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, Nihei Y, Suga Y, Morinaga Y, Akiyama Y, Tsuji T (1998) Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analogues. Bioorg Med Chem Lett 8(22):3153–3158. doi:10.​1016/​S0960-894X(98)00579-4 CrossRefPubMed
21.
Zurück zum Zitat Qiao F, Zuo D, Shen X, Qi H, Wang H, Zhang W, Wu Y (2012) DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080. Cancer Chemother Pharmacol 70(2):259–270. doi:10.1007/s00280-012-1907-x CrossRefPubMed Qiao F, Zuo D, Shen X, Qi H, Wang H, Zhang W, Wu Y (2012) DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080. Cancer Chemother Pharmacol 70(2):259–270. doi:10.​1007/​s00280-012-1907-x CrossRefPubMed
22.
Zurück zum Zitat Romagnoli R, Baraldi PG, Lopez-Cara C, Preti D, Aghazadeh Tabrizi M, Balzarini J, Bassetto M, Brancale A, Fu XH, Gao Y, Li J, Zhang SZ, Hamel E, Bortolozzi R, Basso G, Viola G (2013) Concise synthesis and biological evaluation of 2-Aroyl-5-amino benzo[b]thiophene derivatives as a novel class of potent antimitotic agents. J Med Chem 56(22):9296–9309. doi:10.1021/jm4013938 CrossRefPubMedPubMedCentral Romagnoli R, Baraldi PG, Lopez-Cara C, Preti D, Aghazadeh Tabrizi M, Balzarini J, Bassetto M, Brancale A, Fu XH, Gao Y, Li J, Zhang SZ, Hamel E, Bortolozzi R, Basso G, Viola G (2013) Concise synthesis and biological evaluation of 2-Aroyl-5-amino benzo[b]thiophene derivatives as a novel class of potent antimitotic agents. J Med Chem 56(22):9296–9309. doi:10.​1021/​jm4013938 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8(8):2086–2095CrossRefPubMed Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8(8):2086–2095CrossRefPubMed
25.
Zurück zum Zitat Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265CrossRefPubMed Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265CrossRefPubMed
28.
Zurück zum Zitat Ahmed B, van Eijk LI, Bouma-ter Steege JCA, van der Schaft DWJ, van Esch AM, Joosten-Achjanie SR, Lambin P, Landuyt W, Griffioen AW (2003) Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 105(1):20–25. doi:10.1002/ijc.11010 CrossRefPubMed Ahmed B, van Eijk LI, Bouma-ter Steege JCA, van der Schaft DWJ, van Esch AM, Joosten-Achjanie SR, Lambin P, Landuyt W, Griffioen AW (2003) Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 105(1):20–25. doi:10.​1002/​ijc.​11010 CrossRefPubMed
29.
Zurück zum Zitat Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115(11):2992–3006. doi:10.1172/JCI24586 CrossRefPubMedPubMedCentral Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115(11):2992–3006. doi:10.​1172/​JCI24586 CrossRefPubMedPubMedCentral
Metadaten
Titel
YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo
verfasst von
De Cai
Zhiqing Qiu
Weimin Yao
Yuyu Liu
Haixiang Huang
Sihai Liao
Qun Luo
Liming Xie
Zhixiu Lin
Publikationsdatum
23.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3036-4

Weitere Artikel der Ausgabe 6/2016

Cancer Chemotherapy and Pharmacology 6/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.